I wanted to see what the various brokers are using as for the maintenance requirement for NVAX? I use Etrade and it has been 100% for as long as I can remember. Even with the move up above 10, it hasn't changed. Its strange because INO, which is a similarly sized biotech, has/had a much lower requirement. I'm wondering what is average and whether I can expect this to change.
I have no intention of buying this on margin at the moment, but I'm sitting on a #$%$ ton of options for this NVAX as well, and if/when I want to exercise, it would be nice to have the option not to lay out a ton of cash.
When we get our P2 trial data back on RSV Maternal, how long typically until the Company is ready to move into a P3? Also, I know that with Fast Track designation, we can begin submitting the BLA application on a rolling basis. Would we have already begun submitting parts of it already, or is it only done during the P3?
Finally, if we are fortunate enough to also receive accelerated approval status, what is a likely time frame to get RSV to market? To me, it seems like before the close of 2016, we could be sitting on a marketable RSV vax, given that accelerated approval allows reduces BLA application time down to 6 months, and we may be able to get the BLA done very quickly given that we can do it piece-meal.
If anyone has experience on how this all works, I'd love to get some realistic timeframes for these things. GO NVAX... I bought $7.00 Jan 2016 and 2016 options @ 1.35 and 2.00 respectively back in Oct... best trades of my life.